Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30102643 | 1.00 | RET (0.69) | RET | |
| SCHEMBL22660491 | 0.91 | RET (0.59) | RET | |
| SCHEMBL29615028 | 0.91 | RET (0.72) | RET | |
| SCHEMBL26746128 | 0.89 | RET (0.71) | RET | |
| SCHEMBL31470966 | 0.88 | RET (0.57) | RET | |
| SCHEMBL24180525 | 0.88 | RET (0.69) | RET | |
| SCHEMBL20068897 | 0.87 | RET (0.66) | RET | |
| SCHEMBL29971635 | 0.87 | RET (0.66) | RET | |
| SCHEMBL20069346 | 0.86 | RET (0.64) | RET | |
| SCHEMBL31298367 | 0.86 | RET (0.55) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| EP-3971187-B1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-119684286-A | Synthesis method of key intermediate of celecoxib | 苏州莱安医药化学技术有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-111285873-B | RET inhibitor, pharmaceutical composition thereof and application thereof | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113620944-B | Novel RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071447-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885 |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, CYP4A11, CYP11B1 | RET 89/4885 |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | RET, REL, GOT1 | RET 1/4885 |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | RET 1/4885 |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885 |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | RET, SLC10A2, REL | RET 1/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.